The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
Open accessAbstract
Rifaximin, a poorly absorbed rifamycin derivative, is a promising alternative for the treatment of Clostridium difficile infections. Resistance to this agent has been reported, but no commercial test for rifaximin resistance exists and the molecular basis of this resistance has not been previously studied in C. difficile . To evaluate whether the rifampin Etest would be a suitable substitute for rifaximin susceptibility testing in the clinical setting, we analyzed the in vitro rifaximin susceptibilities of 80 clinical isolates from our collection by agar dilution and compared these results to rifampin susceptibility results obtained by agar dilution and Etest. We found rifaximin susceptibility data to agree with rifampin susceptibility; the MICs of both antimicrobials for all isolates were either very low or very high. Fourteen rifaximin-resistant (MIC, ≥32 μg/ml) unique isolates from patients at diverse locations in three countries were identified. Molecular typing analysis showed that nine (64%) of these isolates belonged to the epidemic BI/NAP1/027 group that is responsible for multiple outbreaks and increased disease severity in the United Kingdom, Europe, and North America. The molecular basis of rifaximin and rifampin resistance in these isolates was investigated by sequence analysis of rpoB , which encodes the β subunit of RNA polymerase, the target of rifamycins. Resistance-associated rpoB sequence differences that resulted in specific amino acid substitutions in an otherwise conserved region of RpoB were found in all resistant isolates. Seven different RpoB amino acid substitutions were identified in the resistant isolates, which were divided into five distinct groups by restriction endonuclease analysis typing. These results suggest that the amino acid substitutions associated with rifamycin resistance were independently derived rather than disseminated from specific rifamycin-resistant clones. We propose that rifaximin resistance in C. difficile results from mutations in RpoB and that rifampin resistance predicts rifaximin resistance for this organism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 5×
“X-ray crystallography analysis of Thermus aquaticus RpoB complexed with rifampin provided an explanation for the locations of the specific mutations found in rifamycin-resistant organisms (2).”
BackgroundInfluential
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Self-citationClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis462 · Cited by 401
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Johnson, S. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.010 · Cited by 397
Self-citationFreeman, J., Vernon, J., Morris, K., Nicholson, S., Todhunter, S., Longshaw, C., & Wilcox, M. H. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.09.017 · Cited by 279
Metadata
- Authors
- O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., & Johnson, S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-08
- Volume
- 52
- Issue
- 8
- Pages
- 2813-2817
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2003497105
- Cited by
- 187
- References
- 1
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile. https://app.cochat.ai/papers/10.1128/aac.00342-08
- The paper
- O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., & Johnson, S. (2008). Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00342-08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.